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Intraluminal conditions in function of 









intraluminal drug & formulation behavior







• double lumen catheter(s)
• blank fluid
• after intake of oral dosage form
• fasted vs fed
Introduction
intraluminal drug & formulation behavior
Sampling of human gastro-intestinal fluids
 characterization: pH, bile salts, phospholipids, drug, excipient…
⇒ intraluminal conditions (after oral drug intake)
descriptive
relation to pharmacokinetics
working mechanisms of formulations
…
 integration in in vitro studies (dissolution / solubility / stability / permeability)
⇒ influence of real intraluminal conditions on drug absorption





poorly water-soluble (0.08 mM in H2O, pH 7, 37 °C)
substrate of the efflux carrier P-gp
Standard formulation (Agenerase®):
soft gelatin capsules


























Prodrug with increased solubility compared to parent drug
→ enhanced intestinal absorption of parent drug!
Introduction
amprenavir / fosamprenavir




To characterize the in vitro behavior of fosamprenavir in the 
Caco-2 model system using different media:
• transport medium (aqueous buffer)
• human intestinal fluids
• “biorelevant” media: FaSSIF (+ taurocholate/phospholipids)
Methods
Stability of fosamprenavir?
transport medium (MES-buffered HBSS, pH 6.5)
“biorelevant” media





• in function of time
• samples pooled per volunteer
• pH / inorganic phosphate
Sampling in function of time
• (filtration)
• analysis of amprenavir and 
fosamprenavir
(HPLC + fluorescence detection)
Caco-2
Results
fosamprenavir in transport medium / Caco-2
Stability of fosamprenavir upon incubation in transport medium?









fosamprenavir in transport medium / Caco-2
Incubation at the apical side of Caco-2 monolayers (60 min, 37°C)
⇒ Conversion to amprenavir: concentration-dependent
pH-dependent


















































60 Amprenavir in acceptor
Amprenavir in donor





































IAP: intestinal alkaline phosphatase
TM
Results
fosamprenavir in HIF / Caco-2
Stability of fosamprenavir upon incubation in HIF?










Stability of fosamprenavir (10 µM) upon incubation in HIF (37°C)








































⇒ Phosphatase activity in HIF, depending on subject.
Results
fosamprenavir in HIF / Caco-2
Incubation at the apical side of Caco-2 monolayers







































⇒ Phosphatase activity of Caco + HIF
High dose of fosamprenavir → amprenavir??
incubation of fosamprenavir 500 µM in HIF  


























High dose of fosamprenavir → amprenavir??
incubation of fosamprenavir 500 µM in HIF  

























⇒ create and maintain supersaturation of amprenavir in HIF
Results
supersaturation in HIF
Supersaturation ⇒ C0 ↑ ⇒ flux?
incubation of amprenavir/fosamprenavir in HIF at Caco-2 monolayers
→ transport of amprenavir in function of time?
APV “1 mM” = suspension 
(in solution: 150 µM)




























APV “1 mM” = suspension 
(in solution: 150 µM)


























FPV 1 mM = solution
Results
supersaturation and flux
incubation of amprenavir/fosamprenavir in HIF at Caco-2 monolayers
→ transport of amprenavir in function of time?
Supersaturation ⇒ C0 ↑ ⇒ flux?
APV “1 mM” = suspension 
(in solution: 150 µM)
FPV 1 mM = solution





























incubation of amprenavir/fosamprenavir in HIF at Caco-2 monolayers
→ transport of amprenavir in function of time?
Supersaturation ⇒ C0 ↑ ⇒ flux?
Results
fosamprenavir in FaSSIF / Caco-2
Stability of fosamprenavir upon incubation in FaSSIF?









fosamprenavir in FaSSIF / Caco-2
Incubation at the apical side of Caco-2 monolayers
(fosamprenavir 10 µM, 60 min, 37°C)










































Incubation at the apical side of Caco-2 monolayers
(fosamprenavir 10 µM, 60 min, 37°C)
TM with different concentrations of inorganic phosphate (Pi)











































⇒ inhibition of intestinal alkaline 
phosphatase by inorganic phosphate
Results
inorganic phosphate
Intraluminal phosphate concentrations? 


















Intraluminal phosphate concentrations? 
⇒ Phosphate-buffered FaSSIF is not compatible with
phosphate ester prodrugs.


















Intraluminal phosphate concentrations? 
⇒ Phosphate-buffered FaSSIF is not compatible with
phosphate ester prodrugs.

























































Incubation at the apical side of Caco-2 monolayers
(fosamprenavir 10 µM, 60 min, 37°C)
TM (MES-buffered HBSS)
+ taurocholate (TC) 3 mM










 Illustration of intraluminal supersaturation of a poorly water-soluble drug 
from its soluble prodrug in real intestinal media.
 Dephosphorylation of fosamprenavir is inhibited by inorganic phosphate
→ biorelevant media!
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